8-K: InMed Pharmaceuticals Reports Positive Preclinical Data and Fiscal Q3 2024 Results

InMed Pharmaceuticals announced positive preclinical data in its Alzheimer's and dry AMD programs, along with its fiscal third quarter 2024 financial results, closing the quarter with $7.9 million in cash.

Summary

• InMed Pharmaceuticals reported its financial results for the third quarter of fiscal year 2024, which ended March 31, 2024.
• The company highlighted positive preclinical data from its Alzheimer's disease (ALZ) and dry Age-related Macular Degeneration (dry AMD) programs.
• BayMedica, InMed's commercial business, generated $3.3 million in revenue for the nine months ended March 31, 2024, an 83% increase compared to the same period last year.
• Quarterly revenue for BayMedica remained flat at $1.2 million, consistent with the previous quarter.
• The company reported a net loss of $5.7 million for the quarter, compared to a net loss of $7.6 million in the same period last year.
• Research and development expenses were $2.6 million for the nine months ended March 31, 2024, down from $3.1 million in the same period last year.
• As of March 31, 2024, InMed had $7.6 million in cash, cash equivalents, and short-term investments.
• The company expects its cash to be sufficient to fund operations into the fourth quarter of calendar year 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed picture with positive preclinical data and revenue growth, but also a net loss and a limited cash runway. The sentiment is cautiously optimistic.

Positives

• The company achieved positive preclinical results in both its Alzheimer's and dry AMD programs.
• BayMedica's revenue increased significantly year-over-year, demonstrating strong commercial growth.
• BayMedica operated as a profitable business unit this quarter.
• The company's net loss decreased compared to the same quarter last year.
• InMed has a strong cash position of $7.6 million.
• The addition of Dr. David G. Morgan to the Scientific Advisory Board enhances the company's expertise in neurodegenerative diseases.

Negatives

• The company experienced a net loss of $5.7 million for the quarter.
• Quarter-over-quarter revenue for BayMedica remained flat.
• The company's cash position decreased from $8.9 million on June 30, 2023, to $7.6 million on March 31, 2024.
• The company has decided not to advance the INM-088 program for glaucoma in the immediate future.

Risks

• The company's future revenue from BayMedica is expected to fluctuate.
• The company's cash runway is only expected to last into the fourth quarter of calendar year 2024.
• The company's success is dependent on the clinical development of its drug candidates.
• The company faces risks associated with the pharmaceutical industry, including regulatory approvals and clinical trial outcomes.

Future Outlook

The company expects its cash to be sufficient to fund its planned operating expenses and capital expenditure requirements into the fourth quarter of calendar year 2024, depending on the level and timing of realizing BayMedica revenues and operating expenses. The company is optimistic about the long-term growth potential in the rare cannabinoids sector, but expects revenue to fluctuate in future quarters.

Management Comments

• Eric A. Adams, InMed President and CEO, stated that the third quarter was another positive quarter for the company.
• Adams also mentioned that the company is highly encouraged by the positive findings in their preclinical programs and is committed to further advancing research in these areas.
• Adams noted that BayMedica operated as a profitable commercial business unit in the current quarter.

Industry Context

The announcement highlights InMed's focus on developing treatments for neurodegenerative diseases like Alzheimer's and dry AMD, which are areas of significant unmet medical need. The company's commercial business, BayMedica, is capitalizing on the growing interest in rare cannabinoids, aligning with broader trends in the health and wellness sector.

Comparison to Industry Standards

• InMed's focus on small molecule drug candidates targeting CB1/CB2 receptors is a common approach in the pharmaceutical industry for developing treatments for neurological and inflammatory conditions.
• The 83% year-over-year revenue growth for BayMedica is a strong performance compared to other companies in the rare cannabinoid sector, although the flat quarter-over-quarter revenue suggests potential volatility.
• The decrease in net loss from $7.6 million to $5.7 million year-over-year is a positive sign, but the company still needs to achieve profitability.
• The cash position of $7.6 million is relatively low for a clinical-stage pharmaceutical company, and the company's guidance that it will only last into the fourth quarter of calendar year 2024 suggests a potential need for additional funding.

Management Changes

Stakeholder Impact

• Shareholders may be encouraged by the positive preclinical data and revenue growth, but concerned about the net loss and limited cash runway.
• Employees may be impacted by the retirement of a key executive.
• Customers of BayMedica may benefit from the company's focus on lowering manufacturing costs and improving margins.
• Suppliers may see increased business opportunities as BayMedica continues to grow.

Next Steps

• InMed will continue to advance its INM-901 program for Alzheimer's disease, with data read-out expected in calendar 3Q 2024.
• The company will continue to develop its INM-089 program for dry AMD.
• InMed will continue to focus on lowering manufacturing costs for BayMedica to improve margins.

Key Dates

Keywords

InMed Pharmaceuticals, Alzheimer's disease, dry AMD, BayMedica, cannabinoids, preclinical data, INM-901, INM-089, financial results, pharmaceutical development